Reiterate Buy: AI memory value and supply tightness support Micron in climbing the “wall of worry”

Overview

Based on discussions with Micron management, this report reiterates a “Buy” rating and US$1,625 price target. The core view is that market positioning and attention are relatively cautious, focused on strategic customer agreements, gross margins, the sustainability of supply tightness, and future capacity additions; however, strengthening demand, rising AI memory value, HBM pricing, and revenue visibility from long-term agreements could allow Micron's earnings to outperform market concerns.

Core views

UBS believes that C2027 memory supply-demand conditions will be tighter than C2026, while Micron's supply to data-center customers remains materially below requested volumes. In the near term, earlier-signed SCA contracts and a larger share of sales entering such contracts may trigger market concerns about peak gross margins; over the long term, UBS is positive on AI increasing memory's share of value. The company has limited new DRAM capacity additions in C2027, with more meaningful net new capacity expected to be concentrated in C2028. In capital allocation, the company prioritizes business investments supporting geographic diversification; while buybacks have potential, expectations regarding their timing should remain cautious.

Analysis framework

The report evaluates management interviews, industry supply-demand and capacity-addition assessments, contract-structure analysis, earnings forecasts, and relative valuation, supplemented by a short-term quantitative survey assessing industry structure, operating trends, and differences versus earnings expectations.

Methodology notes

• Valuation methodsForward 12-month P/E valuation

  Valuation at approximately 11x forward 12-month P/E

  Applies an approximately 11x P/E multiple to C2029 EPS of roughly US$165 and discounts it to C2028E at an approximately 12% cost of equity; the multiple is consistent with Micron's three-year historical average.

• Scenario and cycle analysisThrough-cycle earnings power

  Anchoring long-term value to C2029 earnings

  UBS believes C2029 better reflects through-cycle earnings power under long-term agreements; the model assumes a moderate memory downcycle at that time, but long-term agreements will support the earnings base.

• Quantitative researchQuantitative research review

  Short-term factor probability assessment

  UBS assigns positive scores to industry structure over the next six months, recent operating trends, the next earnings result relative to consensus, and the direction of earnings risk; this framework has a different time horizon from the 12-month stock rating.

Asset mapping & comparison

Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).

• MICRON TECHNOLOGY INC (MU.O)

  Direct coverage target

  Strengths

  AI drives higher memory value; C2027 supply-demand expectations are tightening; HBM ASP and gross margins have upside potential; SCAs and long-term customer arrangements enhance visibility for revenue and capacity planning.

  Weaknesses

  The memory industry has historically been volatile; near-term investors may remain cautious due to concerns about peak gross margins; the pace of buybacks remains unclear.

  Comparison

  The price target implies approximately 11x forward 12-month P/E, broadly in line with the company's three-year historical average; UBS earnings forecasts exceed consensus, at US$184.89 versus US$156.28 for C2027E and US$265.65 versus US$177.70 for C2028E.

  Risks

  Macroeconomic weakness causing demand destruction, ASP declines greater than expected, technology migration or DRAM/NAND capacity-ramp execution falling short of expectations, delayed or accelerated incremental supply, and changes in the pace of AI adoption.

Key data

• 12-month ratingBuyUBS reiterates its rating.
• 12-month price targetUS$1,625.00Unchanged.
• Current share priceUS$1,011.75As of 2026-08-17.
• Forecast share-price upside60.6%Together with a 0.1% forecast dividend yield, forecast stock return is 60.7%.
• C2027 HBM ASP forecastYoY +79%UBS industry blended HBM ASP forecast.
• FY2027 capital expendituresApproximately mid-US$45BManagement reiterated that this estimate remains valid.
• C2027E EPSUS$184.89UBS forecast; consensus is US$156.28.
• C2028E EPSUS$265.65UBS forecast; consensus is US$177.70.

Impact & implications

If strengthening demand and supply constraints persist, rising HBM prices and profitability could be catalysts for a valuation re-rating. SCAs, take-or-pay arrangements, and long-term customer arrangements outside agreements mean disclosed RPO may understate actual revenue visibility, supporting a more constructive view of earnings stability. At the same time, more concentrated new capacity additions in C2028 and near-term gross-margin changes could intensify trading-related concerns that the cycle is peaking.

Risks

• Global economic weakness could reduce memory demand and pressure valuation and the price target.
• If ASP declines exceed expectations, both earnings and the share price could come under pressure.
• DRAM and NAND process scaling is complex, and technology migration progressing more slowly than expected could create downside risk.
• The timing of new supply additions, especially C2028 capacity ramp-ups, could alter the industry's supply-demand balance.
• If AI adoption in servers, robotics, and automobiles is slower than expected, memory-content growth may fall short of expectations.
• SCA contracts with fixed or range-based pricing may constrain near-term earnings elasticity when spot prices rise.

What to watch

• The degree of C2027 supply-demand tightness and changes in data-center customer allocations.
• HBM ASP, HBM gross margins, and the convergence of pricing differentials versus DDR.
• Progress toward the target of covering more than 50% of revenue with SCAs, the proportion of take-or-pay agreements, and pricing terms.
• Differences between disclosed RPO and revenue visibility implied by actual customer allocations and long-term agreement coverage.
• Start-up and ramp progress for ID1, Tongluo, Singapore HBM back-end packaging, ID2, and Hiroshima Fab 15 expansion.
• Whether FY2027 capital expenditures remain at approximately mid-US$45B, and buyback plans following the expiration of CHIPS Act-related restrictions.
• Performance of the next earnings update relative to consensus expectations and gross-margin trends.